• SIGN IN
  • GET HELP
  •  

    Home Study Details


    Program Type

    Home Study Webcast

    Credits

    1 Contact Hour(s)

    Release Date

    Monday, November 2, 2020

    Offline Date

    Sunday, May 2, 2021

    ACPE Expiration Date

    Sunday, October 29, 2023

    Target Audience

    Pharmacist, Nurse

    Cost

    $0.00

    • Overview

      Early studies show that patients with COVID-19 appear to be at a higher risk for thrombotic complications like venous thromboembolism (VTE).  VTE is already among the leading causes of death from cardiovascular disease.  So, in addition to the traditional risk factors for VTE, practitioners must consider both the indirect effects as well as the direct effects of the COVID infection as they contribute to even greater risk of the consequences of VTE. This program will review the current literature and evidence regarding the frequency of VTE in patients with COVID, as well as the available guidance and evidence-based literature regarding the use of anticoagulation therapies in patients with COVID or patients recovering from COVID.

      Handouts

      • Slide Document :   20256H01_2pp.pdf
      • Slide Document :   20256H01_6pp.pdf

      Financial Support By

      Bristol-Myers Squibb and Pfizer Alliance
    • Pharmacist

      Review the evidence-based literature and current assessment of the need for anticoagulation therapy for prevention of VTE in patients with COVID-19 and/or post COVID-19 patients.
      Choose an anticoagulation treatment plan for VTE in COVID-19 positive patients based on patient specific factors and special considerations to improve patient outcomes.
      Compare and contrast the indications, advantages and potential adverse effects of direct oral anticoagulants for the treatment of VTE.

      Nurse

      Review the evidence-based literature and current assessment of the need for anticoagulation therapy for prevention of VTE in patients with COVID-19 and/or post COVID-19 patients.
      Compare and contrast the indications, advantages and potential adverse effects of direct oral anticoagulants for the treatment of VTE.
      Choose an anticoagulation treatment plan for VTE in COVID-19 positive patients based on patient specific factors and special considerations to improve patient outcomes.
    • Activity Type

      Application

      CE Broker

      20-797328

      Universal Activity Number

      Pharmacist 0798-0000-20-256-H01-P
      Nurse 0798-0000-20-256-H01-N

      ACPE PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

      PharmCon is an approved course provider for continuing education for nurses by the Florida Board of Nursing. PharmCon is also recognized by the California Board of Nursing as a provider of nursing programs.

      In order to obtain a Statement of Credit, participants must score no less than a 70% on the activity's test and complete a program evaluation.


    HARDWARE REQUIREMENTS
    Standard Windows/Mac System
    iPad or iPhone
    Minimum screen resolution: 1024x768
    Speakers or headphones
     


    SOFTWARE REQUIREMENTS
    Microsoft Edge
    Internet Explorer 8.0 or higher
    Google Chrome
    Safari
    Firefox 3.0.3 or higher


    NETWORK REQUIREMENTS
    Broadband Internet Connection:
    T1, Hi-speed DSL or Cable
    4G cellular connection
     
     

    This continuing education activity is held as copyright by PharmCon, Inc. Through this notice, PharmCon, Inc. grants permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).